Radiotherapy of Hodgkin's Disease
Hodgkin's original 7 cases had in common lymph node and splenic enlargement, cachexia, and a fatal outcome. Medical attitudes change slowly and until recently it was accepted that this was an incurable disease; treatment should be deferred until symptoms indicated it imperatively or, if given in the early stages, should be by the lowest dose of X-rays which would cause the clinical disappearance of a tumour mass without producing a reaction. This attitude was reflected in a masterly review of all known facts published in 1948 by Hoster et al. for the Hodgkin's Disease Research Foundation. The authors, while being careful to avoid the term 'incurable', found the condition divided as a rule into three stages; a period of latency with glandular enlargement, a stage of progression, and a period of cachexia preceding death, a sequence which left little room for cure.
In the late 1940s, however, it began to be felt that the number of early cases treated by radiotherapy and surviving was more than could be accounted for by errors in diagnosis. It was also postulated that the start of the disease was often unicentric and its progress for a long time centripetal from gland group to adjacent group before there was any spread by the blood stream: it might be possible to contain the whole growth in an X-ray field, and to eradicate it by a course of radiotherapy taken to high dosage. Modern treatment is based on these suppositions.
Treatment had to be aggressive - Jelliffe (1965) , in a review of cases from the Middlesex Hospital, showed that doses of 2500 rad in twelve days or 4000 rad in twenty-eight days were required to ensure against recurrence in the treated area: these are high doses and, delivered by kilovoltage radiation, are associated with troublesome immediate reactions and some late morbidity. Easson & Russell (1963) , however, demonstrated from an analysis of a series from the Christie Hospital, Manchester, that cases surviving a decade following treatment along these lines stood little more chance of dying than a normal population of similar age and sex distribution, suggesting that the disease had in fact been cured.
Fortunately, radiotherapeutic equipment has improved enormously in recent years, and the greatest advantages of megavoltage and telecobalt therapy are a tissue-sparing effect and precision of treatment. Vital structures can be shielded and adequate dosage ensured even when the disease is extensive.
Proper treatment depends on proper assessment, which has given rise to difficulties in the past. Until lately we were usually ignorant of the state of the abdominal glands, but now we are greatly helped by lymphography and laparotomy. Assessment is time-consuming, but it is now apparent that a few weeks investigating the patient is time well spent: undue haste leads to inappropriate therapy.
Many problems of treatment remain to be solved. Some of these, lending themselves ideally to examination by clinical trial, are being investigated actively in this country, the continent and the United States. Should the early case, where only the glands on one side of the neck are apparently involved, receive treatment to the neck only or should one irradiate the apparently normal mediastinum as well, knowing that this is the common site of the first recurrence? Should one irradiate the whole gland areas of the trunk when there is known to be involvement both above and below the diaphragm, or is such a patient better treated by one of the excellent new schedules of chemotherapy? Chemotherapy has been used in clinical practice for approximately twenty years and the subject has now come of age. While it is still true that the majority of common malignancies are not amenable to treatment with cytotoxic drugs, there are a few human tumours, notably chorioepithelioma, Burkitt's lymphoma and lymphoblastic leukemia, which are curable by drugs alone. In other tumours the cure rate is increasing with the combined use of radiotherapy and chemotherapy and there is reason to believe that Hodgkin's disease is in this category. Because of this possibility it is important that the right drugs be applied at the right time and in the right way.
Localized Hodgkin's disease should be treated by radiotherapy, but before deciding that it is the treatment of choice a very detailed investigation of the patient must be made to delineate the true extent of the disease. This investigation must include X-rays of the chest, lymphangiography and intravenous pyelography, as well as liver function tests, ESR and blood count. Liver and spleen scanning may be helpful but laparotomy with splenectomy is being advocated now as a means of increasing the accuracy of staging.
If the disease is widespread, chemotherapy is the treatment of choice, especially if the patient has fever, sweats or weight loss.
Many drugs have been found useful in the treatment of Hodgkin's disease, including vinblastine and cyclophosphamide, but with single agents, given continuously in relatively low doses, complete remission has rarely occurred in more than 25 % of cases. More recently combinations of cytotoxic drugs have been given with a view to increasing their anti-tumour effect while not increasing their toxicity. The best regime so far devised consists of vincristine 1.5-2.0 mg given intravenously on Days 1 and 8 and mustine hydrochloride 6-10 mg intravenously on Days 1 and 8, together with procarbazine 50-150 mg and prednisone 40 mg orally, daily from Days 1 to 8 inclusive. This regime is usually referred to as MOPP.
When given to patients with recurrent Hodgkin's disease, remission is achieved in most patients and is complete in 50-60%. In our own series at the Royal Marsden Hospital the median length of complete remissions was 23 months. Complete remissions are achieved in 75 % of cases if MOPP is given as a first treatment and the median length of remission in one large prospective study was 96 weeks, compared with 55 weeks using vinblastine and cyclophosphamide singly.
The MOPP regime is given at least six times over approximately six months and studies are under way to see whether some kind of maintenance therapy after six months of MOPP can increase the length of remissions still further. The treatment is inconvenient for a patient who is feeling well and is at work, but is not dangerous if given properly. Treatment of the poorly differentiated lymphoma, that is lymphosarcoma and reticulum cell sarcoma, has been following similar lines to those just described. Unfortunately the results of treatment even for local disease have not been as good as in Hodgkin's disease. This may be due to earlier dissemination which is not treated by local radiotherapy, and chemotherapy is now being given to patients earlier in the hope of improving results. When the disease is widespread, complete remissions can be achieved in approximately 80% of cases but the median length of remissions is disappointingly short, approximately 35 weeks. Again, combination chemotherapy is better than single agents, but in this case a combination of cyclophosphamide, prednisone and vincristine has proved most effective.
The results, then, in poorly differentiated non-Hodgkin's lymphoma, are disappointing. However, since it is known that in animal tumours the correct choice of drugs, dose schedules and timing of therapy may be all-important in producing a good cure rate, we may be optimistic that more effective regimes will be available in the near future.
